FP-Class prostaglandin analogs have demonstrated utility for the treatment of glaucoma and
ocular hypertension. A series of novel FP prostaglandin analogs was designed to optimize …

OBJECTIVE: Prostaglandin receptor analogs lower intraocular pressure (IOP) and are used
for the treatment of glaucoma. This study aimed to compare the safety, tolerability and …

In a randomized, double-masked, placebo-controlled study, 0.25 μg (n= 11) or 0.5 μg (n=
13) of prostaglandin F 2α-1-isopropyl ester (PGF 2α-IE) was applied topically twice daily for …

More than 100 years ago, the treatment of glaucoma was among the most advanced of
ophthalmology disciplines, encompassing both specific medical therapy (pilocarpine) and …

Glaucoma is a leading cause of irreversible blindness with estimations raising the number of
patients at 79.6 million worldwide by the year 2020 [1]. Lowering the intraocular pressure …

Purpose: The use of a dual prostaglandin E3 (EP3) and prostaglandin F (FP) receptor
agonist is a novel approach for the reduction of intraocular pressure (IOP) in open angle …

Background/Aim: Prostaglandin analogues (PGAs) are a first-line medical treatment for
glaucoma because of their powerful intraocular pressure (IOP) lowering effect, few systemic …

Several prostaglandins (PGs), their prodrugs, and their analogues have been shown to
reduce intraocular pressure (IOP) in normotensive volunteers and in patients with elevated …

Glaucoma encompasses a group of optic neuropathies characterized by complex and often
elusive etiopathology, involvihttng neurodegeneration of the optic nerve in conjunction with …

Purpose: Tafluprost is a new prostaglandin F2α (PGF2α) derivative in development for the
treatment of glaucoma. Tafluprost is the first PGF2α analogue with a preservative‐free …